V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 280008807 | 280009162 | 1.69 | 70 | Palliative (P) | 2018-03-26 | 2018-03-27 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 280028918 | CISPLATIN + GEMCITABINE |
| 280008808 | 280011755 | 1.73 | 74.4 | Palliative (P) | 2014-01-18 | 2014-01-26 | Carboplatin + Paclitaxel (3 weekly) | N | N | 280028921 | CARBOPLATIN + PACLITAXEL |
| 280008809 | 280006040 | null | 79.2 | null | 2014-02-27 | 2014-03-10 | Doxorubicin + Ifosfamide | Y | N | 280028924 | DOXORUBICIN + IFOSFAMIDE |
| 280008810 | 280006041 | 1.93 | 76.4 | Neo-adjuvant (N) | 2013-12-06 | 2013-12-08 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 280028928 | GEMCITABINE |
| 280008811 | 280009164 | 1.76 | null | Curative (C) | 2016-03-28 | 2016-03-28 | Doxorubicin + Olaratumab | 02 | null | 280028929 | DOXORUBICIN + OLARATUMAB |
| 280008812 | 280006042 | 1.75 | null | Palliative (P) | null | 2014-04-16 | VAI (Ifos 3g/m2) | null | null | 280028930 | IRINOTECAN + TEMOZOLOMIDE |
| 280008813 | 280006043 | 1.67 | 75.15 | Disease modification (D) | 2013-06-13 | 2013-07-16 | DE-ESCALATE TRIAL | 02 | N | 280028935 | DE-ESCALATE TRIAL |
| 280008814 | 280009165 | 1.57 | 66.7 | Palliative (P) | null | 2017-01-31 | Carboplatin + Etoposide iv&po | N | N | 280028939 | CARBOPLATIN + ETOPOSIDE |
| 280008815 | 280009165 | null | null | Palliative (P) | 2017-02-06 | 2017-02-12 | CISPLATIN + FLUOROURACIL | 02 | N | 280028939 | CISPLATIN + FLUOROURACIL |
| 280008816 | 280006044 | 1.7 | 68.1 | Adjuvant (A) | 2014-12-19 | 2014-12-21 | CARBOPLATIN + PACLITAXEL | 2 | N | 280028949 | CARBOPLATIN + PACLITAXEL |
| 280008817 | 280006045 | 1.57 | 65 | Adjuvant (A) | 2015-11-09 | 2016-04-24 | Doxorubicin + Ifosfamide | 02 | N | 280028950 | DOXORUBICIN + IFOSFAMIDE |
| 280008818 | 280006047 | 1.52 | 64 | Curative (C) | 2013-02-15 | 2013-02-16 | Irinotecan + Modified De Gramont | 02 | N | 280028957 | IRINOTECAN + MDG |
| 280008819 | 280010664 | 1.73 | 119.3 | Palliative (P) | 2014-10-14 | 2014-10-27 | Cetuximab+Cisplatin+FU (> Cycle 2) | null | null | 280028961 | CETUXIMAB + CISPLATIN + FU |
| 280008820 | 280006048 | 1.8 | 68.4 | Curative (C) | 2018-11-17 | 2018-12-08 | Cisplatin +Fluorouracil (3 wk) | null | null | 280028965 | CISPLATIN + FLUOROURACIL |
| 280008821 | 280010665 | 1.71 | 62.2 | null | 2015-03-28 | 2015-04-28 | CISPLATIN + FLUOROURACIL | N | Y | 280028967 | CISPLATIN + FLUOROURACIL |
| 280008822 | 280006049 | 1.71 | 83.6 | Palliative (P) | 2017-01-30 | 2017-03-08 | CYCLOPHOSPHAMIDE | 02 | N | 280028975 | CYCLOPHOSPHAMIDE |
| 280008823 | 280009169 | 1.59 | 53.9 | Palliative (P) | 2017-10-21 | 2017-11-04 | Irinotecan + Temozolomide | 2 | N | 280028979 | IRINOTECAN + MDG |
| 280008824 | 280006050 | 1.82 | 51.5 | Palliative (P) | 2015-08-27 | 2015-09-04 | Irinotecan + Modified De Gramont | N | N | 280028980 | IRINOTECAN + MDG |
| 280008825 | 280006051 | 1.67 | 79.2 | Curative (C) | 2018-07-11 | 2018-08-11 | VAI (Ifos 3g/m2) | null | null | 280028985 | IRINOTECAN + MDG |
| 280008826 | 280006051 | 1.67 | 59.4 | Palliative (P) | 2016-04-09 | 2016-04-25 | DE-ESCALATE TRIAL | 02 | N | 280028985 | DE-ESCALATE TRIAL |
| 280008827 | 280006054 | 1.76 | 73.9 | Neo-adjuvant (N) | 2014-10-05 | 2014-10-18 | Cyclophosphamide oral | 2 | N | 280028989 | CYCLOPHOSPHAMIDE |
| 280008828 | 280006055 | 1.66 | 54.8 | Palliative (P) | 2017-01-12 | 2017-01-19 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | N | 280028992 | CETUXIMAB + CISPLATIN + FU |
| 280008829 | 280010669 | 0 | 64.2 | Disease modification (D) | 2013-10-25 | 2013-11-29 | FLUOROURACIL + IRINOTECAN | N | N | 280028993 | VAI |
| 280008830 | 280010669 | 1.67 | 59.2 | null | 2012-10-10 | 2013-01-05 | VAI (Ifos 3g/m2) | 02 | N | 280028993 | IRINOTECAN + TEMOZOLOMIDE |
| 280008831 | 280006056 | null | 95 | null | 2016-05-23 | 2016-10-29 | Doxorubicin + Ifosfamide | N | N | 280029001 | DOXORUBICIN + IFOSFAMIDE |
| 280008832 | 280009174 | 1.86 | 96.3 | Palliative (P) | 2016-09-15 | 2016-09-15 | EW EuroEwing 99 : VActI | 02 | N | 280029001 | EURO-EWING |
| 280008833 | 280006058 | 1.86 | 96.3 | Palliative (P) | 2015-04-14 | 2015-04-22 | EW EuroEwing 99 : VActI | 02 | N | 280029006 | EURO-EWING |
| 280008834 | 280010671 | 1.74 | 65.2 | Curative (C) | 2018-07-04 | 2018-07-08 | Carboplatin + Etoposide iv&po | N | N | 280029007 | CARBOPLATIN + ETOPOSIDE |
| 280008835 | 280006059 | 0 | 36.3 | Palliative (P) | null | 2018-01-26 | Cisplatin +Fluorouracil (3 wk) | null | null | 280029009 | CISPLATIN + FLUOROURACIL |
| 280008836 | 280006061 | 0 | 88.9 | Adjuvant (A) | 2014-12-04 | 2014-12-05 | Oxaliplatin + Modified de Gramont | 02 | N | 280029011 | OXALIPLATIN + MDG |
| 280008837 | 280006062 | null | null | Palliative (P) | 2018-05-24 | 2018-05-25 | DE-ESCALATE TRIAL | N | N | 280029012 | DE-ESCALATE TRIAL |
| 280008838 | 280006063 | 1.65 | null | Curative (C) | 2018-04-14 | 2018-04-28 | Doxorubicin + Olaratumab | null | N | 280029014 | DOXORUBICIN + OLARATUMAB |
| 280008839 | 280006065 | 1.65 | 63.6 | Palliative (P) | 2016-07-14 | 2016-07-21 | Cisplatin +Fluorouracil (3 wk) | N | N | 280029015 | CISPLATIN + FLUOROURACIL |
| 280008840 | 280012136 | 1.83 | 91.55 | Curative (C) | null | 2016-08-22 | CISPLATIN + GEMCITABINE | N | N | 280029015 | CISPLATIN + GEMCITABINE |
| 280008841 | 280012136 | 1.74 | 60 | null | null | 2016-12-05 | EURO-EWING | Y | null | 280029015 | EURO-EWING |
| 280008842 | 280010675 | null | null | Palliative (P) | 2017-07-02 | 2017-07-03 | Oxaliplatin + Modified de Gramont | 01 | N | 280029023 | OXALIPLATIN + MDG |
| 280008843 | 280006073 | 1.76 | 69.9 | Palliative (P) | 2015-01-10 | 2015-01-15 | Irinotecan + Temozolomide | 02 | N | 280029031 | IRINOTECAN + TEMOZOLOMIDE |
| 280008844 | 280006073 | 1.65 | 58.5 | Palliative (P) | null | 2019-03-10 | CISPLATIN + FLUOROURACIL | null | null | 280029031 | CISPLATIN + FLUOROURACIL |
| 280008845 | 280006074 | 1.52 | 78.7 | null | 2014-08-12 | 2014-08-23 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | N | 280029036 | CETUXIMAB + CISPLATIN + FU |
| 280008846 | 280006075 | 1.73 | 72.3 | Palliative (P) | 2015-08-25 | 2015-10-20 | EW EuroEwing 99 : VIDE | 02 | Y | 280029036 | EURO-EWING |
| 280008847 | 280010676 | null | 79 | Palliative (P) | 2018-11-02 | 2018-11-20 | FLUOROURACIL + IRINOTECAN | Y | N | 280029038 | IRINOTECAN + TEMOZOLOMIDE |
| 280008848 | 280006076 | 1.7 | 70 | Palliative (P) | 2015-08-26 | 2015-08-26 | GEMCITABINE | 02 | N | 280029042 | GEMCITABINE |
| 280008849 | 280006077 | 1.66 | 60.4 | Neo-adjuvant (N) | 2017-02-06 | 2017-02-07 | FLUOROURACIL + IRINOTECAN | N | N | 280029044 | IRINOTECAN + MDG |
| 280008850 | 280006079 | 0 | 74.4 | Palliative (P) | 2016-12-03 | 2016-12-28 | VAI (Ifos 3g/m2) | N | N | 280029045 | IRINOTECAN + MDG |
| 280008851 | 280006080 | 1.58 | 115.9 | Curative (C) | 2014-09-28 | 2015-03-05 | EW Rel rEECur Irinotecan/Temozolomide | N | N | 280029049 | IRINOTECAN + TEMOZOLOMIDE |
| 280008852 | 280009184 | 1.75 | 64.8 | Palliative (P) | 2014-10-14 | 2014-11-03 | EW Rel rEECur Irinotecan/Temozolomide | 2 | N | 280029051 | IRINOTECAN + MDG |
| 280008853 | 280006081 | 1.7 | 81.6 | Palliative (P) | 2014-11-23 | 2014-11-23 | VAI (Ifos 3g/m2) | null | null | 280029057 | IRINOTECAN + MDG |
| 280008854 | 280006086 | 1.58 | 86.15 | Palliative (P) | 2018-08-03 | 2019-02-21 | FLUOROURACIL + IRINOTECAN | 02 | N | 280029062 | IRINOTECAN + MDG |
| 280008855 | 280006087 | 1.66 | 69.85 | null | 2013-05-12 | 2013-05-22 | Etoposide + Ifosfamide (3 days) | 2 | N | 280029067 | ETOPOSIDE + IFOSFAMIDE |
| 280008856 | 280006088 | null | 65.9 | Curative (C) | 2018-07-03 | 2018-07-22 | Cisplatin+Gemcitabine (gallbladder) | null | null | 280029070 | CISPLATIN + GEMCITABINE |